Company

Cyfuse Biomedical

サイフューズ

4892 · TSE · Pharmaceutical

Financials Company only

Revenue¥231m+324.3% year on yearCompany only · FY12/25

Ordinary profit−¥761mCompany only · FY12/25

Revenue

¥708mFY12/21

¥374mFY12/22

¥61.1mFY12/23

¥54.4mFY12/24

¥231mFY12/25

Ordinary profit

¥145mFY12/21

−¥433mFY12/22

−¥586mFY12/23

−¥870mFY12/24

−¥761mFY12/25

Op. cash flow

¥162mFY12/21

−¥404mFY12/22

−¥562mFY12/23

−¥761mFY12/24

−¥535mFY12/25

Employees23 peopleFY12/25

Average salary¥9.35mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history

Five-year history
Fiscal year	Revenue	Ordinary profit	EPS	Total assets	Net assets	Op. cash flow
FY12/25	¥231.0m+324.3% year on year	−¥761m	−¥86.78	¥4.27bn	¥2.76bn	−¥535m
FY12/24	¥54.4m−10.9% year on year	−¥870m	−¥108.34	¥3.52bn	¥2.54bn	−¥761m
FY12/23	¥61.1m−83.7% year on year	−¥586m	−¥75.42	¥4.21bn	¥3.20bn	−¥562m
FY12/22	¥374.5m−47.1% year on year	−¥433m	−¥177.67	¥4.82bn	¥3.77bn	−¥404m
FY12/21	¥708.2m	¥145m	¥285.53	¥2.65bn	¥1.90bn	¥162m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XV4M · Japan GAAP. Each figure's years come from one report's five-year summary.